Retinal Tissue Perfusion reduced by 42% in MS !!!

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.
Post Reply
leonardo
Family Member
Posts: 76
Joined: Tue Apr 09, 2013 9:56 am
Been thanked: 1 time

Retinal Tissue Perfusion reduced by 42% in MS !!!

Post by leonardo » Sat May 04, 2019 1:12 pm

hi,

please check this new study:

https://www.ncbi.nlm.nih.gov/pubmed/31046490
Retinal Tissue Perfusion in Patients with Multiple Sclerosis.

Abstract

PURPOSE: The goal of this work was to determine whether the retinal tissue perfusion (RTP) is impaired in patients with multiple sclerosis (MS).

METHODS: Seventy-four patients [66 relapsing-remitting MS (RRMS) and 8 clinically isolated syndrome (CIS)] and 74 age- and gender-matched healthy controls were recruited. RTP was calculated as the retinal blood flow (measured using retinal function imager) supplying the macular area divided by the corresponding tissue volume of the inner retina from the inner limiting membrane to the outer plexiform layer, as measured by ultrahigh resolution optical coherence tomography.

RESULTS: The RTP in the MS group was 2.37 ± 0.59 nl/s/mm3 (mean ± standard deviation), which was significantly lower than the control group (4.06 ± 0.89 nl/s/mm3, P < 0.001), reflecting a decrease of 42%. The blood flow volume was 2.50 ± 0.50 nl/s in MS, which was 45% lower than in the control group (4.56 ± 0.91 nl/s, P < 0.001). In addition, the tissue volume of the inner retina was significantly lower than in the control group (P < 0.05). The RTP in patients with MS was significantly correlated with the retinal blood flow volume (r = 0.84, P < 0.001) and retinal tissue volume (r = -0.56, P < 0.001). However, the retinal blood flow in patients with MS was not related to the tissue volume (r = -0.06, P = 0.59).

CONCLUSIONS: Impaired retinal tissue perfusion occurred in patients with MS, which could be developed as a possible biomarker in monitoring disease progression in MS.

User avatar
frodo
Family Elder
Posts: 1261
Joined: Wed Dec 02, 2009 3:00 pm
Has thanked: 2 times
Been thanked: 1 time
Contact:

Re: Retinal Tissue Perfusion reduced by 42% in MS !!!

Post by frodo » Sun May 05, 2019 10:23 am

Interesting. Whatever MS is, it is clear that it has nothing to do with the standard autoimmune model

vesta
Family Elder
Posts: 604
Joined: Thu Jul 12, 2012 9:10 am
Location: Paris, France
Been thanked: 6 times
Contact:

Re: Retinal Tissue Perfusion reduced by 42% in MS !!!

Post by vesta » Sun May 05, 2019 10:52 am

frodo wrote:
Sun May 05, 2019 10:23 am
Interesting. Whatever MS is, it is clear that it has nothing to do with the standard autoimmune model
In my opinion, MS is a CNS fluid circulation disorder caused by many factors. gristy56 has proposed an interesting treatment in this sense thinking that magnetite in the blood injures the myelin. When ElliotB used the "desatascador" device to eliminate the magnetite, his vision dramatically improved. See below quotes.

Re: Desatascador An informal, totally unscientific 'test'
Edit Report Quote
Post by vesta » Fri Nov 02, 2018 9:37 am

ElliotB wrote:
"After 34 years of MS I'm still surprised by the small improvements"...

ElliotB's question: Why do you think the vision improves the way it does? I am still maintaining the improvements I experienced.

Vesta's response: If you think of the magnetite as a nano-particle which pokes holes in the eye vessels, that makes perfect sense to me, more so than a simple venous blood reflux. So maybe by expelling the magnetite you are protecting your eyes.

Best regards, Vesta

User avatar
frodo
Family Elder
Posts: 1261
Joined: Wed Dec 02, 2009 3:00 pm
Has thanked: 2 times
Been thanked: 1 time
Contact:

Re: Retinal Tissue Perfusion reduced by 42% in MS !!!

Post by frodo » Mon May 06, 2019 5:27 am

Maybe related to this (S1P is the kind of cells that fingolimod targets)

Sphingosine 1-phosphate (S1P) and inflammation

https://www.ncbi.nlm.nih.gov/pubmed/31049553

Abstract

Sphingosine 1-phosphate (S1P) [...] provides a basis of immunomodulatory drugs targeting S1P1 receptor such as FTY720, an immunosuppressive drug approved in 2010 as the first oral treatment for relapsing-remitting multiple sclerosis.

The S1P-S1P receptor signaling system also plays important roles in maintenance of vascular integrity since it suppresses sprouting angiogenesis and regulates vascular permeability. Dysfunction of the S1P-S1P receptor signaling system results in various vascular defects, such as exaggerated angiogenesis in developing retina and augmented inflammation due to increased permeability [...]

This review highlights the importance of the S1P-S1P receptor signaling system in inflammatory processes. We also describe our recent findings regarding a specific S1P chaperone, apolipoprotein M, that anchors to high-density lipoprotein and contributes to shaping the endothelial-protective and anti-inflammatory properties of high-density lipoprotein.

vesta
Family Elder
Posts: 604
Joined: Thu Jul 12, 2012 9:10 am
Location: Paris, France
Been thanked: 6 times
Contact:

Re: Retinal Tissue Perfusion reduced by 42% in MS !!!

Post by vesta » Tue May 07, 2019 2:40 am

frodo wrote:
Mon May 06, 2019 5:27 am
Maybe related to this (S1P is the kind of cells that fingolimod targets)

Sphingosine 1-phosphate (S1P) and inflammation

https://www.ncbi.nlm.nih.gov/pubmed/31049553

Abstract

Sphingosine 1-phosphate (S1P) [...] provides a basis of immunomodulatory drugs targeting S1P1 receptor such as FTY720, an immunosuppressive drug approved in 2010 as the first oral treatment for relapsing-remitting multiple sclerosis.

The S1P-S1P receptor signaling system also plays important roles in maintenance of vascular integrity since it suppresses sprouting angiogenesis and regulates vascular permeability. Dysfunction of the S1P-S1P receptor signaling system results in various vascular defects, such as exaggerated angiogenesis in developing retina and augmented inflammation due to increased permeability [...]

This review highlights the importance of the S1P-S1P receptor signaling system in inflammatory processes. We also describe our recent findings regarding a specific S1P chaperone, apolipoprotein M, that anchors to high-density lipoprotein and contributes to shaping the endothelial-protective and anti-inflammatory properties of high-density lipoprotein.
Greetings:

I believe Cheerleader sees MS as veinous arteriosclerosis as does "violin". Violin has been advised to take EDTA capsules and/or undergo IV Chelation. Diet change can apparently treat arteriosclerosis in 2 weeks, hence the importance of an anti-inflammatory diet in MS. gristy56 has observed that current MS research sees MS as a chemical rather than a physical problem (which this article illustrates). His "desatascador" treatment is intended to eliminate magnetite which he believes damages the myelin. Advised that venoplasty for CCSVI could help someone with chronic Lyme disease, "violin" felt much better after her venoplasty treatment cleaned out her veins.

So let's put this together. Let's say that EBV illness (Mono) causes vein inflammation which clogs up the veins to impede blood flow. Magnetite may damage the optic nerve as illustrated by ElliotB's recovery using the "desatascador" (which shouldn't be ignored).

Let's start with the idea that MS is a CNS fluid circulation problem which can be caused by multiple factors. Infections and poor diet may obstruct the veins which need to be addressed as treatment. The immune system reaction is secondary. Better to treat the primary problem.

Regards, Vesta

Post Reply
  • Similar Topics
    Replies
    Views
    Last post